home
***
CD-ROM
|
disk
|
FTP
|
other
***
search
/
The Arsenal Files 6
/
The Arsenal Files 6 (Arsenal Computer).ISO
/
health
/
med9603.zip
/
M9630559.TXT
< prev
next >
Wrap
Text File
|
1996-02-27
|
2KB
|
30 lines
Document 0559
DOCN M9630559
TI Specific considerations for cost-effectiveness studies in AIDS.
DT 9603
AU Bozzette SA; Medical Service, San Diego Veteran's Affairs Medical
Center, CA; 92161, USA.
SO J Acquir Immune Defic Syndr Hum Retrovirol. 1995;10 Suppl 4:S23-7.
Unique Identifier : AIDSLINE MED/96075586
AB HIV disease is an epidemic with unique features that make it a
challenging topic for pharmacoeconomic analysis. Unlike many other
illnesses, the lengthy course of HIV disease, its relatively high
incidence among young and productive individuals, and management of drug
toxicities have an enormous impact on total costs. Methodologic
difficulties discussed include strategies for handling the effect of
having a few high-cost cases and for summarizing effectiveness. The
advantages and disadvantages of different measures of effectiveness,
such as health status, quality of life, and utility in the setting of
HIV disease, as well as the scaling of measures and approaches to
handling death, are also addressed.
DE Acquired Immunodeficiency Syndrome/DRUG THERAPY/*ECONOMICS/
EPIDEMIOLOGY Age Factors Antiviral Agents/ADVERSE EFFECTS/ECONOMICS
Cost-Benefit Analysis/*ECONOMICS Disease Progression Health Status
Human Quality of Life Support, Non-U.S. Gov't Support, U.S. Gov't,
Non-P.H.S. Support, U.S. Gov't, P.H.S. JOURNAL ARTICLE REVIEW
REVIEW, TUTORIAL
SOURCE: National Library of Medicine. NOTICE: This material may be
protected by Copyright Law (Title 17, U.S.Code).